Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Medical Treatment of Cysticercosis—Effective

Medical Treatment of Cysticercosis—Effective Abstract The first studies on specific drug therapy for neurocysticercosis (NCC) appeared more than one decade ago.1-5 As usually occurs with pioneer work with many other drugs, such studies only included anecdotal case reports or small series of patients with different forms of the disease. Therefore, the efficacy of anticysticercal drugs was difficult to evaluate. A new age of knowledge on medical treatment for NCC began when Sotelo and coworkers6,7 published the first controlled trials of praziquantel therapy in patients with parenchymal brain cysts. The authors used historical controls to demonstrate that viable cysticerci may live unchanged for several years within the brain parenchyma and that a course with praziquantel at daily doses of 50 mg per kilogram of body weight for 15 days destroys more than 60% of these cysts in less than 3 months. Using a similar design, several articles from different areas of the world further References 1. Robles C, Chavarría M. Presentación de un caso clínico de cisticercosis cerebral curado médicamente con un nuevo fármaco: praziquantel . Salud Pub Mex . 1979;21:603-618. 2. Gomez JG, Peña G, Patiño R, Pradilla G. Neurocysticercosis treated with praziquantel . Neurol Colombia . 1981;5:665-670. 3. Botero D, Castaño S. Treatment of cysticercosis with praziquantel in Colombia . Am J Trop Med Hyg . 1982;31:811-821. 4. Spina-Franca A, Nobrega JPS, Livramento JA, Machado LR. Administration of praziquantel in neurocysticercosis . Tropenmed Parasitol . 1982; 33:1-4. 5. Lombardo L, Vasconcelos D, Cruz-Segura H. Tratamiento de la cisticercosis con praziquantel: informe preliminar de diez casos . Gac Med Mex . 1983;119:17-22. 6. Sotelo J, Escobedo F, Rodriguez-Carbajal J, Torres B, Rubio-Donnadieu F. Therapy of parenchymal brain cysticercosis with praziquantel . N Engl J Med . 1984;301:1001-1007.Crossref 7. Sotelo J, Torres B, Rubio-Donnadieu F, Escobedo F, Rodriguez-Carbajal J. Praziquantel in the treatment of neurocysticercosis: long-term follow-up . Neurology . 1985;35:752-754.Crossref 8. Gómez J, Bustamante-Zuleta E, Sánchez E. Tratamiento de la cisticercosis con praziquantel: presentación de 50 casos . Neurol Colombia . 1985; 9:29-35. 9. Robles C, Sedano AM, Vargas-Tentori N, Galindo-Virgen S. Long-term results of praziquantel therapy in neurocysticercosis . J Neurosurg . 1987;66: 359-363.Crossref 10. Vasconcelos D, Cruz-Segura H, Mateos-Gómez H, Zenteno-Alanís G. Selective indications for the use of praziquantel in the treatment of brain cysticercosis . J Neurol Neurosurg Psychiatry . 1987; 50:383-388.Crossref 11. vanDellen JR, McKeown CP. Praziquantel (pirazynoisoquinolone) in active cerebral cysticercosis . Neurosurgery . 1988;22:92-96. 12. Escobedo F, Penagos P, Rodriguez J, Sotelo J. Albendazole therapy for neurocysticercosis . Arch Intern Med . 1987;147:738-741.Crossref 13. Sotelo J, Penagos P, Escobedo F, Del Brutto OH. Short course of albendazole therapy for neurocysticercosis . Arch Neurol . 1988;45:1130-1133.Crossref 14. Escobedo F, Sotelo J, Penagos P, Rodriguez J, Del Brutto OH. Albendazole therapy for human neurocysticercosis: a controlled trial with computerized tomography and magnetic resonance imaging . Acta Leidensia . 1989;57:247-254. 15. Carpio A, Santillán F, León P, Borrero A, Tinoco L. New treatment of brain cysticercosis with albendazole . Ann Neurol . 1988;24:144. Abstract. 16. Sotelo J, Escobedo F, Penagos P. Albendazole VB praziquantel for therapy of neurocysticercosis: a controlled trial . Arch Neurol . 1988;45:532-534.Crossref 17. Sotelo J, Del Brutto OH, Penagos P, et al. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis . J Neurol . 1990;237:69-72.Crossref 18. Cruz M, Cruz I, Horton J. Albendazole vs praziquantel in the treatment of cerebral cysticercosis: clinical evaluation . Trans R Soc Trop Med Hyg . 1991;85:244-247.Crossref 19. Takayanagui OM, Jardim E. Therapy for neurocysticercosis: comparison between albendazole and praziquantel . Arch Neurol . 1992;49:290-294.Crossref 20. Jung H, Hurtado M, Sánchez M, Medina MT, Sotelo J. Plasma and CSF levels of albendazole and praziquantel in patients with neurocysticercosis . Clin Neuropharmacol . 1990:13:559-564. 21. Del Brutto OH, Sotelo J. Albendazole therapy for subarachnoid and ventricular cysticercosis . J Neurosurg . 1990;72:816-817.Crossref 22. Santoyo H, Corona R, Sotelo J. Total recovery of visual function after treatment for cerebral cysticercosis . N Engl J Med . 1991;324:1137-1139. 23. Del Brutto OH, Sotelo J, Aguirre R, Díaz-Calderón E, Alarcón TA. Albendazole therapy for giant subarachnoid cysticerci . Arch Neurol . 1992; 49:535-538.Crossref 24. Del Brutto OH, Sotelo J, Roman GC. Therapy for neurocysticercosis: a reappraisal. Clin Infect Dis. In press. 25. Mitchell WG, Crawford TO. Intraparenchymal cerebral cysticercosis in children: diagnosis and treatment . Pediatrics . 1988;82:76-82. 26. Alcalá H, Sánchez E, Malagón J, Dávila G. Neurocysticercosis in Mexican children: report of 29 cases . Ann Neurol . 1988;2:341. Abstract. 27. Kramer LD, Locke GE, Byrd SE, Daryabagi J. Cerebral cysticercosis: documentation of natural history with CT . Radiology . 1989;170:459-462.Crossref 28. Medina MT, Cordova S, Genton P, Sotelo J, Dravet C, Montoya MC. Prognosis of epilepsy in neurocysticercosis: the effect of anticysticercal drug therapy . Epilepsia . 1991;32( (suppl 1) ):110-111. Abstract. 29. Del Brutto OH, Santibañez R, Noboa CA, Aguirre R, Díaz E, Alarcón TA. Epilepsy due to neurocysticercosis: analysis of 203 patients . Neurology . 1992; 42:389-392.Crossref 30. Vazquez N, Sotelo J. The course of seizures after treatment for cerebral cysticercosis . N Engl J Med . 1992;327:696-701.Crossref 31. Kramer LD. Antihelminthic therapy for neurocysticercosis . Arch Neurol . 1990;47:1059.Crossref 32. Chandy MJ, Rajshekhar V, Ghosh S, et al. Single small enhancing CT lesions in Indian patients with epilepsy: clinical, radiological and pathological considerations . J Neurol Neurosurg Psychiatry . 1991;54:702-705.Crossref 33. Ralshekhar V. Etiology and management of single small CT lesions in patients with seizures: understanding a controversy . Acta Neurol Scand . 1991;84:465-470.Crossref 34. Del Brutto OH. The use of albendazole in patients with single lesions enhanced on contrast CT . N Engl J Med . 1993;328:356-357.Crossref 35. Rangel R, Torres B, Del Brutto O, Sotelo J. Cysticercotic encephalitis: a severe form in young females . Am J Trop Med Hyg . 1987;36:387-392. 36. Sotelo J, Del Brutto OH. Therapy for neurocysticercosis . Childs Nerv Syst . 1987;3:208-211.Crossref 37. Del Brutto OH. Diagnosis and management of cysticercosis . J Trop Geogr Neurol . 1992;2:1-9. 38. Sotelo J, Guerrero V, Rubio F. Neurocysticercosis: a new classification based on active and inactive forms . Arch Intern Med . 1985;145:442-445.Crossref 39. Del Brutto OH, Sotelo J. Neurocysticercosis: an update . Rev Infect Dis . 1988;10:1075-1087.Crossref 40. deGhetaldi LD, Norman RM, Douville AW Jr. Cerebral cysticercosis treated biphasically with dexamethasone and praziquantel . Ann Intern Med . 1983;99:179-181.Crossref 41. Ciferri F. Delayed CSF reaction to praziquantel . Lancet . 1988;1:642-643.Crossref 42. Del Brutto OH. Delayed CSF reaction to praziquantel . Lancet . 1988;2:341.Crossref 43. Del Brutto OH. Cysticercosis and cerebrovascular disease: a review . J Neurol Neurosurg Psychiatry . 1992;55:252-254.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Neurology American Medical Association

Medical Treatment of Cysticercosis—Effective

Archives of Neurology , Volume 52 (1) – Jan 1, 1995

Loading next page...
 
/lp/american-medical-association/medical-treatment-of-cysticercosis-effective-aTvJm1uPd0
Publisher
American Medical Association
Copyright
Copyright © 1995 American Medical Association. All Rights Reserved.
ISSN
0003-9942
eISSN
1538-3687
DOI
10.1001/archneur.1995.00540250110021
Publisher site
See Article on Publisher Site

Abstract

Abstract The first studies on specific drug therapy for neurocysticercosis (NCC) appeared more than one decade ago.1-5 As usually occurs with pioneer work with many other drugs, such studies only included anecdotal case reports or small series of patients with different forms of the disease. Therefore, the efficacy of anticysticercal drugs was difficult to evaluate. A new age of knowledge on medical treatment for NCC began when Sotelo and coworkers6,7 published the first controlled trials of praziquantel therapy in patients with parenchymal brain cysts. The authors used historical controls to demonstrate that viable cysticerci may live unchanged for several years within the brain parenchyma and that a course with praziquantel at daily doses of 50 mg per kilogram of body weight for 15 days destroys more than 60% of these cysts in less than 3 months. Using a similar design, several articles from different areas of the world further References 1. Robles C, Chavarría M. Presentación de un caso clínico de cisticercosis cerebral curado médicamente con un nuevo fármaco: praziquantel . Salud Pub Mex . 1979;21:603-618. 2. Gomez JG, Peña G, Patiño R, Pradilla G. Neurocysticercosis treated with praziquantel . Neurol Colombia . 1981;5:665-670. 3. Botero D, Castaño S. Treatment of cysticercosis with praziquantel in Colombia . Am J Trop Med Hyg . 1982;31:811-821. 4. Spina-Franca A, Nobrega JPS, Livramento JA, Machado LR. Administration of praziquantel in neurocysticercosis . Tropenmed Parasitol . 1982; 33:1-4. 5. Lombardo L, Vasconcelos D, Cruz-Segura H. Tratamiento de la cisticercosis con praziquantel: informe preliminar de diez casos . Gac Med Mex . 1983;119:17-22. 6. Sotelo J, Escobedo F, Rodriguez-Carbajal J, Torres B, Rubio-Donnadieu F. Therapy of parenchymal brain cysticercosis with praziquantel . N Engl J Med . 1984;301:1001-1007.Crossref 7. Sotelo J, Torres B, Rubio-Donnadieu F, Escobedo F, Rodriguez-Carbajal J. Praziquantel in the treatment of neurocysticercosis: long-term follow-up . Neurology . 1985;35:752-754.Crossref 8. Gómez J, Bustamante-Zuleta E, Sánchez E. Tratamiento de la cisticercosis con praziquantel: presentación de 50 casos . Neurol Colombia . 1985; 9:29-35. 9. Robles C, Sedano AM, Vargas-Tentori N, Galindo-Virgen S. Long-term results of praziquantel therapy in neurocysticercosis . J Neurosurg . 1987;66: 359-363.Crossref 10. Vasconcelos D, Cruz-Segura H, Mateos-Gómez H, Zenteno-Alanís G. Selective indications for the use of praziquantel in the treatment of brain cysticercosis . J Neurol Neurosurg Psychiatry . 1987; 50:383-388.Crossref 11. vanDellen JR, McKeown CP. Praziquantel (pirazynoisoquinolone) in active cerebral cysticercosis . Neurosurgery . 1988;22:92-96. 12. Escobedo F, Penagos P, Rodriguez J, Sotelo J. Albendazole therapy for neurocysticercosis . Arch Intern Med . 1987;147:738-741.Crossref 13. Sotelo J, Penagos P, Escobedo F, Del Brutto OH. Short course of albendazole therapy for neurocysticercosis . Arch Neurol . 1988;45:1130-1133.Crossref 14. Escobedo F, Sotelo J, Penagos P, Rodriguez J, Del Brutto OH. Albendazole therapy for human neurocysticercosis: a controlled trial with computerized tomography and magnetic resonance imaging . Acta Leidensia . 1989;57:247-254. 15. Carpio A, Santillán F, León P, Borrero A, Tinoco L. New treatment of brain cysticercosis with albendazole . Ann Neurol . 1988;24:144. Abstract. 16. Sotelo J, Escobedo F, Penagos P. Albendazole VB praziquantel for therapy of neurocysticercosis: a controlled trial . Arch Neurol . 1988;45:532-534.Crossref 17. Sotelo J, Del Brutto OH, Penagos P, et al. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis . J Neurol . 1990;237:69-72.Crossref 18. Cruz M, Cruz I, Horton J. Albendazole vs praziquantel in the treatment of cerebral cysticercosis: clinical evaluation . Trans R Soc Trop Med Hyg . 1991;85:244-247.Crossref 19. Takayanagui OM, Jardim E. Therapy for neurocysticercosis: comparison between albendazole and praziquantel . Arch Neurol . 1992;49:290-294.Crossref 20. Jung H, Hurtado M, Sánchez M, Medina MT, Sotelo J. Plasma and CSF levels of albendazole and praziquantel in patients with neurocysticercosis . Clin Neuropharmacol . 1990:13:559-564. 21. Del Brutto OH, Sotelo J. Albendazole therapy for subarachnoid and ventricular cysticercosis . J Neurosurg . 1990;72:816-817.Crossref 22. Santoyo H, Corona R, Sotelo J. Total recovery of visual function after treatment for cerebral cysticercosis . N Engl J Med . 1991;324:1137-1139. 23. Del Brutto OH, Sotelo J, Aguirre R, Díaz-Calderón E, Alarcón TA. Albendazole therapy for giant subarachnoid cysticerci . Arch Neurol . 1992; 49:535-538.Crossref 24. Del Brutto OH, Sotelo J, Roman GC. Therapy for neurocysticercosis: a reappraisal. Clin Infect Dis. In press. 25. Mitchell WG, Crawford TO. Intraparenchymal cerebral cysticercosis in children: diagnosis and treatment . Pediatrics . 1988;82:76-82. 26. Alcalá H, Sánchez E, Malagón J, Dávila G. Neurocysticercosis in Mexican children: report of 29 cases . Ann Neurol . 1988;2:341. Abstract. 27. Kramer LD, Locke GE, Byrd SE, Daryabagi J. Cerebral cysticercosis: documentation of natural history with CT . Radiology . 1989;170:459-462.Crossref 28. Medina MT, Cordova S, Genton P, Sotelo J, Dravet C, Montoya MC. Prognosis of epilepsy in neurocysticercosis: the effect of anticysticercal drug therapy . Epilepsia . 1991;32( (suppl 1) ):110-111. Abstract. 29. Del Brutto OH, Santibañez R, Noboa CA, Aguirre R, Díaz E, Alarcón TA. Epilepsy due to neurocysticercosis: analysis of 203 patients . Neurology . 1992; 42:389-392.Crossref 30. Vazquez N, Sotelo J. The course of seizures after treatment for cerebral cysticercosis . N Engl J Med . 1992;327:696-701.Crossref 31. Kramer LD. Antihelminthic therapy for neurocysticercosis . Arch Neurol . 1990;47:1059.Crossref 32. Chandy MJ, Rajshekhar V, Ghosh S, et al. Single small enhancing CT lesions in Indian patients with epilepsy: clinical, radiological and pathological considerations . J Neurol Neurosurg Psychiatry . 1991;54:702-705.Crossref 33. Ralshekhar V. Etiology and management of single small CT lesions in patients with seizures: understanding a controversy . Acta Neurol Scand . 1991;84:465-470.Crossref 34. Del Brutto OH. The use of albendazole in patients with single lesions enhanced on contrast CT . N Engl J Med . 1993;328:356-357.Crossref 35. Rangel R, Torres B, Del Brutto O, Sotelo J. Cysticercotic encephalitis: a severe form in young females . Am J Trop Med Hyg . 1987;36:387-392. 36. Sotelo J, Del Brutto OH. Therapy for neurocysticercosis . Childs Nerv Syst . 1987;3:208-211.Crossref 37. Del Brutto OH. Diagnosis and management of cysticercosis . J Trop Geogr Neurol . 1992;2:1-9. 38. Sotelo J, Guerrero V, Rubio F. Neurocysticercosis: a new classification based on active and inactive forms . Arch Intern Med . 1985;145:442-445.Crossref 39. Del Brutto OH, Sotelo J. Neurocysticercosis: an update . Rev Infect Dis . 1988;10:1075-1087.Crossref 40. deGhetaldi LD, Norman RM, Douville AW Jr. Cerebral cysticercosis treated biphasically with dexamethasone and praziquantel . Ann Intern Med . 1983;99:179-181.Crossref 41. Ciferri F. Delayed CSF reaction to praziquantel . Lancet . 1988;1:642-643.Crossref 42. Del Brutto OH. Delayed CSF reaction to praziquantel . Lancet . 1988;2:341.Crossref 43. Del Brutto OH. Cysticercosis and cerebrovascular disease: a review . J Neurol Neurosurg Psychiatry . 1992;55:252-254.Crossref

Journal

Archives of NeurologyAmerican Medical Association

Published: Jan 1, 1995

References